Key Points
Class switch did not occur in Dsg3-specific BCR knock-in mice in a steady state.
Stimulation driving anti-Dsg3 IgG production induced a pemphigus phenotype in mice.
Class switch–constraining immune state prevented pemphigus phenotype development.
Abstract
Pemphigus vulgaris is an autoimmune blistering disease caused by IgG targeting desmoglein 3 (Dsg3), an adhesion molecule of keratinocytes. Anti-Dsg3 IgG production is prevented in healthy individuals, but it is unclear how Dsg3-specific B cells are regulated. To clarify the immunological condition regulating Dsg3-specific B cells, a pathogenic anti-Dsg3 Ig (AK23) knock-in mouse was generated. AK23 knock-in B cells developed normally without undergoing deletion or acquiring an anergic phenotype in vivo. The knock-in B cells showed Ca2+ influx upon IgM cross-linking and differentiated into AK23-IgG+ B cells after LPS and IL-4 stimulation in vitro that induced a pemphigus phenotype after adoptive transfer into Rag2−/− mice. However, the knock-in mouse itself produced AK23-IgM but little IgG without blisters in vivo. Dsg3 immunization and skin inflammation caused AK23-IgG production and a pemphigus phenotype in vivo. Furthermore, Fcgr2b deficiency or haploinsufficiency spontaneously induced AK23-IgG production and a pemphigus phenotype with poor survival rates in AK23 knock-in mice. To assess Fcgr2b involvement in Ig class-switch efficiency, postswitch transcripts of B cells were quantified and significantly higher in Fcgr2b−/− and Fcgr2b+/− mice than wild-type mice in a gene dose-dependent manner. Finally, RNA sequencing revealed reduced expression of FCGR2B and FcγRIIB-related genes in patient B cells. These results indicated that Dsg3-specific B cells do not spontaneously perform pathogenic class switching in vivo, and pemphigus phenotype induction was prevented under normal conditions. Attenuated FcγRIIB signaling is also one of the drivers for pathogenic class switching and is consistent with immunological features identified from clinical samples. This study unveiled a characteristic immune state silencing autoreactive B cells in mice.
Footnotes
This work was supported by Grants-in-Aid for Scientific Research (B) (11470089, 13557026) from the Japan Society for the Promotion of Science to S.K.; a Grant-in-Aid for Scientific Research (C) (22590437) to H.F.; a Grant-in-Aid for Scientific Research (S) (21229014) to M.A.; Grants-in-Aid for Scientific Research (A) (26253065) to M.A. and (19H01051) to H.T. from the Japan Society for the Promotion of Science; a Grant-in-Aid for Scientific Research on Innovative Areas (18073015) to S.K. from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Health and Labor Sciences Research Grants for Research on Allergic Disease and Immunology (H20-Immunology-General-006) to S.K. from the Ministry of Health, Labour and Welfare of Japan; and Keio University Gijuku Academic Development Funds to H.F.
The online version of this article contains supplemental material.
Abbreviations used in this article
- BM
- bone marrow
- Cy7
- cyanine 7
- DNFB
- 2,4-dinitro-1-fluorobenzene
- Dsg3
- desmoglein 3
- ES
- embryonic stem
- ki
- knock-in
- MOG
- myelin oligodendrocyte glycoprotein
- PST
- postswitch transcript
- PV
- pemphigus vulgaris
- rDsg3
- recombinant desmoglein 3
- RF
- rheumatoid factor
- sLN
- skin-draining lymph node
- tg
- transgenic
- Treg
- regulatory T
- WT
- wild type
- Received August 9, 2021.
- Accepted November 22, 2021.
- Copyright © 2022 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.